BI-9627 is a potent, selective inhibitor of sodium-hydrogen exchanger isoform 1 (NHE1) with pHi change IC50 of 6 nM, displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform.

BI-9667 (BI9667) is a potent, selective CCR1 antagonist..

BI-99179 is a potent and selective inhibitor of type I fatty acid synthase (FAS) with IC50 of 79 nM.

BIA 10-2474 is an inhibitor of fatty acid amide hydrolase (FAAH) with IC50 values of 50 to 70mg/kg in various rat brain regions.

Biapenem is a carbapenem antibiotic.

biBET is a potent, selective, bivalent inhibitor of BET bromodomains with pKd of 8.3/7.3/11 for BRD4(1)/BRD4(2)/BRD4(1,2), respectively.

BIBO 3304 is a potent, selective, nonpeptide neuropeptide Y Y1 receptor antagonist with IC50 of 0.38 and 0.72 nM for human and the rat Y1 receptor, respectively.

BIBR 1087 SE is an intermediate metabolite of dabigatran etexilate.

BIBR 1532 is a potent, selective, non-competitive telomerase inhibitor with IC50 of 100 nM.

BIBU1361 is a potent, selective, orally active EGFR inhibitor with IC50 of 3 nM, shows weak activity against HER2 (IC50=280 nM) and no inhibition on IGF1R, HGFR, Src, and VEGFR2 (IC50>10 uM).

BIBU1361 is a potent, selective, orally active EGFR inhibitor with IC50 of 3 nM, shows weak activity against HER2 (IC50=280 nM) and no inhibition on IGF1R, HGFR, Src, and VEGFR2 (IC50>10 uM).

Bicyclomycin benzoate is an antibiotic exhibiting activity against a broad spectrum of Gram-negative bacteria and against the Gram-positive bacterium.

BIIL260 is the active metabolite of BIIL284, shows high affinity to LTB4 receptor on isolated human neutrophil cell membranes with Ki of 1.7 nM.

BILH-434 is a potent HPV11 E1/E2/DNA complex inhibitor that binds to the transactivation domain (TAD) of E2 protein with a Kd of 40 nM, has an IC50 of 180 nM in the E1-E2-ori complex formation assay..

BIO 8898 is a synthetic, CD40-CD154 co-stimulatory interaction inhibitor that inhibits the TNF family cytokine CD40L binding to CD40-Ig with a potency of IC50=25 uM.

BIO1211 (BIO-1211) is a potent, highly specific integrin α4β1 (VLA-4) inhibitor with Kd/IC50 of 20 pM/4 nM for the activated form of α4β1.

BIO124 (BIO-124) is a modest inhibitor of the PICK1-GluA2 interaction with IC50 of 0.51 uM in FP assays, binds to the PDZ domain of PICK1..

BIO922 (BIO 922, BIO-922) is a small molecule PICK1 inhibitor that specificly blocks the PDZ domain-mediated interaction between GluA2 and PICK1 (IC50=69 nM), blocks the effects of Aβ on synaptic transmission and surface receptors.

Bio-AMS is a chemical inhibitor of Mycobacterium tuberculosis biotin protein ligase ( MtBPL) with Kd of 0.865 nM.

Biperiden (KL 373) is a centrally-acting antiparkinsonian agent that functions as a selective central M1 cholinoreceptors blocker..

Biperiden Hcl (NSC 170950, NSC 84989) is a centrally-acting antiparkinsonian agent that functions as a selective central M1 cholinoreceptors blocker..

Bisantrene is a highly effective antitumor drug, targets eukaryotic type II topoisomerases.

Bisindolylmaleimide X is a cell-permeable, reversible, ATP-competitive protein kinase C (PKC) inhibitor (IC50 = 15 nM, rat brain PKC).

Bisindolylmaleimide X is a cell-permeable, reversible, ATP-competitive protein kinase C (PKC) inhibitor (IC50 = 15 nM, rat brain PKC).

Bisperoxovanadium (bpV(phen) potassium hydrate) is a bisperoxovanadium (bpV) compound which inhibits several different protein tyrosine phosphatases (PTPs), with selectivity for PTEN (IC50 =38 nM), also inhibits the vascular endothelial PTP, PTP-β (IC50=3

Bisphenol A is a starting material for the synthesis of plastics, primarily certain polycarbonates and epoxy resins, as well as some polysulfones and certain niche materials. It exhibits estrogen-mimicking, hormone-like properties.

Bis-T-23 is a small molecule that stimulates actin-dependent dynamin oligomerization and promotes dynamin GTPase activity, increases actin polymerization in injured podocytes.

Bitertanol is a broad-spectrum triazole fungicide that is active against a variety of fungi, including V. inaequalis and V. pirina.

Bitopertin, also known as RG1678, is a potent and selective inhibitor of GlyT1 with an EC50 of 30nM.

BIX 02565 is a novel ribosomal S6 kinase 2 (RSK2) inhibitor with an IC50 of 1.1 nM.

BIX02189 is a selective inhibitor of MEK5 with IC50 of 1.5 nM, also inhibits ERK5 catalytic activity with IC50 of 810 nM, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2.

Bizine is a phenelzine analog that inhibits LSD1 with Ki of 59 nM, displays 23-fold, 63-fold, and >100-fold selectivity for LSD-1 over MAOA, MAOB, and LSD2 respectively.

BJE6-106 (B106) is a potent, selective PKCδ inhibitor with IC50 of 50 nM, displays excellent selectivity over classical PKC isozymes (a 1,000-fold PKCδ selectivity over PKCα).

BKI-1369 is a bumped kinase inhibitor (BKI). BKI-1369 increases human Ether-a-go-go-related gene (hERG)-inhibitory activity with an IC50 of 1.52 μM. BKI-1369 reduces the parasite burden and diseases severity in the gnotobiotic pig model. BKI-1369 has been well characterized for potency, stability, metabolism, toxicity, pharmacokinetics and is potent against C. parvum in infected mice and calves.

BL-1020 is an ester of GABA and perphenazine, fuctions as orally-active antipsychotic agent and acts as a D2 antagonist and GABA agonist.

BL5923 (BL-5923) is a potent, highly specific, orally available inhibitor of CCR1 with IC50 of 20.4 and 22.8 nM for human and mouse CCR1, resepctively.

BL-918 is a small molecule activator of ULK1 with EC50 of 24 nM (243% kinase activity at 100 nM), induces autophagy via the ULK complex in SH-SY5Y cells.

BL-AD008 (BL-AD 008) is a novel small molecule, dual-target activator targeting AMPK/ZIPK; demonstrates remarkable anti-proliferative activities toward cervical cancer cells and could induce apoptosis by death-receptor and mitochondrial pathways; also sho

Blasticidin S hydrochloride is a nucleoside antibiotic isolated from Streptomyces griseochromogenes. Blasticidin S is a potent inhibitor of protein synthesis in both prokaryotic and eukaryotic cells.

Blonanserin(AD-5423) is a D2/5-HT2 receptor antagonist, atypical antipsychotic.

BLT-1 is an irreversible Scavenger receptor class B member I (SR-BI) inhibitor that blocks SR-BI-mediated selective lipid uptake and bidirectional cholesterol flux with an IC50 of 50 nM; significantly inhibits baicalin-induced cholesterol efflux in THP-1 macrophages.

BLU-667 (Pralsetinib) is a highly potent, selective, next generation RET inhibitor with IC50 of 0.3-0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion.

BLU-667 trans form is the trans form of BLU-667, which is a highly potent, selective, next generation RET inhibitor..

BM-1197 is a potent, specific dual inhibitor of Bcl-2 and Bcl-xL with Ki of <1 nM, shows >1,000-fold selectivity over Mcl-1.

BM-635 is a small molecule anti-mycobacterial compound acting by inhibiting the mycobacterial membrane protein Large 3 (MmpL3).

BM-957 is a highly potent, dual Bcl-2 and Bcl-xL inhibitor with Ki of <1 nM for both, IC50 of 5.4 and 6.0 nM, respectively.

Bm-MPK1-IN-15b is a potent, orally bioavailable inhibitor of B. malayi stress-activated kinase Bm-MPK1 with IC50 of 24 nM.

BMN-673 (8R,9S) is the (8R,9S) enantiomer of BMN-673. BMN 673 is a novel PARP inhibitor with IC50 of 0.58 nM(PARP1). It does not inhibit PARG and is highly sensitive to PTEN mutation.

BMP signaling agonist sb4 is a small molecule BMP signaling agonist with EC50 of 73.6 nM, enhances the efficacy of BMPs and activates endogenous BMP4 target genes.

BMS 695735 is a potent, selective IGF-1R inhibitor with IC50 of 34 nM.

A novel potent, selective, orally active human 11β-HSD1 inhibitor with IC50 of 3.0 nM.

BMS-189453 (BMS189453, BMS453) is a synthetic retinoid that acts as an agonist of RARβ and an antagonist of RARα and RARγ.

BMS-2 is a potent MET kinase inhibitor with an IC50 value of 1.8nM. It also possesses potent inhibitory activity against Flt-3 and VEGFR-2 kinases, IC50 values of 4nM and 27nM respectively.

BMS-211 is a prodrug of the parent pan-CK2 inhibitor BMS-699..

BMS-212 is a potent and selective stimulator of glucokinase (GK) (EC50 = 35 nM) that is promisingly used as an antidiabetic.

BMS-214662 is a potent and selective farnesyl transferase inhibitor with potent antitumor activity with an IC50 of 1.35 nM.

BMS-265246 is a potent and selective CDK1/2 inhibitor for CDK1/cyclin B and CDK2/cyclin E with IC50 of 6 nM and 9 nM, respectively.

BMS-394136 is a potent, selective IKur/Kv1.5inhibitor, increases atrial action potential duration (APD) and prolongs AERP but not VERP in both rabbits and beagles..

BMS433771 is a potent, orally active RSV fusion inhibitor, exhibits excellent potency against multiple laboratory and clinical isolates of both group A and B viruses with mean EC50 of 20 nM.

BMS-457 is a potent and selective CCR1 antagonist with binding IC50 of 0.8 nM, >1,000-fold selectivity against other CC family receptors.

BMS-538203 is a highly efficient HIV integrase inhibitor and antiviral agent.

BMS-564929 is a potent, selective androgen receptor modulator (SARM) that binds to AR with Ki of 2.11 nM.

BMS-595 (BMS595) is a novel potent, selective, ATP-competitive casein kinase 2 (CK2) inhibitor with IC50 of 1.3 nM (CKα).

BMS-599626 (AC-480) is a potent, selective inhibitor of EGFR and HER2 with IC50 of 20 nM and 30 nM.

BMS-641988 is a potent, selective, nonsteroidal androgen receptor antagonist with Ki of 1.7 nM, MDA-MB-453 cell IC50 of 16 nM.

BMS-654457 is a potent, reversible and direct inhibitor of factor XIa (FXa) with Ki of 0.4 nM.

BMS-699 (BMS699) is a novel potent, selective, ATP-competitive casein kinase 2 (CK2) inhibitor with IC50 of 0.1 nM (CKα).

BMS-741672 is a potent, selective CCR2 antagonist for the treatment of neuropathic pain..

BMS-751324 is a novel clinical prodrug of BMS-582949, which is a highly selective p38α MAPK inhibitor with IC50 of 13 nM.

BMS-779788(XL652) is a novel small-molecule modulator of the Liver X Receptor (LXR), a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders.

BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7/15 nM; also inhibits Ron, Axl and Flt3 with IC50 of <3 nM; a prodrug of BMS-817378.

BMS-795311 is a potent and orally available CETP inhibitor with IC50 of 3.8 nM, inhibits cholesteryl ester (CE) transfer with IC50 of 0.22 uM.

BMS-806 (BMS 378806) is a small molecule gp120/CD4 inhibitor with an IC50 of median 5 nM.

BMS-813160 is a dual CCR2/CCR5 chemokine antagonist.

BMS-817399 is a potent, selective, orally bioavailable CCR1 antagonist with binding IC50 of 1 nM, inhibits MIP-1α-induced chemotaxis with IC50 of 6 nM.

BMS-818251 (BMS818251) is a novel potent, small-molecule inhibitor of HIV-1 entry with EC50 of 0.019 nM against e laboratory-adapted HIV-1 strain NL4-3.

BMS-823778 (BMS823778) is an orally available, potent and selective inhibitor of 11βHSD-1 with IC50 of 2.3 nM, displays >10,000-fold selectivity over 11βHSD-2.

BMS 833923 is an orally bioavailable inhibitor of Smo. It blocks binding of BODIPY cyclopamine (IC50 = 21 nM) and inhibits Gli activation in cell lines that express wild-type Smo or activated mutant forms of Smo (IC50s = 6-35 nM). BMS 833923 robustly inhi

BMS-869780 is a potent γ-secretase modulator (GSM) that decreases Aβ1-42 (IC50=5.1 nM) and Aβ1-40 (IC50=25.1 nM) and increases Aβ1-37 and Aβ1-38 without inhibiting overall levels of Aβ peptides or other APP processing intermediates.

BMS-871 is a potent, orally active pan-Notch inhibitor with IC50 of 4/1/4/3 nM for Notch1/2/3/4, respectively.

BMS-884775 is a potent, selective P2Y1 antagonist with IC50 of 0.12 nM.

BMS-901715 is a potent, selective adapter protein-2 associated kinase 1 (AAK1) inhibitor..

BMS-906024 is a highly potent, selective inhibitor of γ-secretase mediated signaling of Notch1/2/3/4 receptors with IC50 of 1.6/0.7/3.4/2.9 nM, respectively.

BMS-919373 is a potent I(Kur)/Kv1.5 channel blocker with IC50 of 50 nM, with selectivity versus hERG, Na, Ca channels and reduced the level of brain penetration.

BMS-933043 is a novel highly selective, potent α7 nAChR partial agonist with binding Ki of 3.3 and 8.1 nM for rat and human α7, respectively.

BMS-952048 is a positive allosteric modulator of mGluR5 with EC50 of 10 nM..

BMS-961955 is an potent, allosteric inhibitor of HCV NS5B polymerase with EC50 of 7.9/4.3 nM for GT 1b/1a replicon respectively.

BMS-983970 (BMS983970) is a potent, orally active, pan-Notch inhibitor, demonstrates robust anti-tumor activity at tolerated doses in multiple tumor xenograft models..

BMS-984923 (BMS-984923) is a potent silent allosteric modulator (SAM) of mGluR5 with competitive antagonism of MPEPy binding with Ki of 0.6 nM, but has no detectable agonist and antagonist activity at mGluR5 signaling.

BMS-986115 is an orally bioavailable, γ-secretase and pan-Notch inhibitor with potential antineoplastic activity.

BMS-986118 is a potent and selective GPR40 agonist with EC50 of 70 and 63 nM for hGPR40 and mGPR40, shows no PPARγ activity (EC50>47 uM).

BMS-986122 is a potent positive allosteric modulator of μ-opioid receptor, significantly increases the inhibition of forskolin-stimulated adenylyl cyclase activity produced by an EC10 (30 pM) concentration of endomorphin-I in CHO-μ cells..

BMS-986163 is a water-soluble phosphate prodrug of BMS-986169, which is a novel GluN2B negative allosteric modulator (Ki=4.0 nM)..

BMS-986165 is a selective, potent, allosteric inhibitor of tyrosine kinase 2 (Tyk2).

BMS-986169 is a novel GluN2B negative allosteric modulator, demonstrates high binding affinity for the GluN2B allosteric site (Ki=4.0 nM) and selective inhibition of GluN2B receptor function (IC50=24 nM) in cells.

BMS-986187 is a novel potent, positive allosteric modulator of δ-opioid receptor with EC50 of 30 nM, 100-fold selectivity over μ-opioid receptor..

BMS-986202 is a clinical Tyk2 inhibitor that binds to Tyk2 JH2 with IC50 of 0.19 nM and shows remarkably selectivity over other kinases including Jak family members.

BMT-046091 (BMT046091) is a potent and selective AAK1 inhibitor with IC50 of 2.8 nM.

BMT-090605 (BMT 090605, BMT090605) is a potent, selective adapter protein-2 associated kinase 1 (AAK1) inhibitor with IC50 0.6 nM.

BMT-145027 is a potent mGluR5 PAM with no inherent mGluR5 agonist activity.

BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.

BMY 7378 is a multi-targeted inhibitor of α2C-adrenoceptor and α1D-adrenoceptor with pKi of 6.54 and 8.2, respectively, and acts as a mixed agonist and antagonist for 5-HT1A receptor with pKi of 8.3.

BNC-1 is a small molecule modulator of Amyloid pathology by promoting phosphorylation and activation of Elk-1, a transcriptional repressor of presenilin-1 but not presenilin-2.

BNC105 is a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy.

BNM-III-170 is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.

BNM-III-170 TFA salt is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.

BNS-22 is a small-molecule inhibitor of DNA topoisomerase II, inhibits kinetoplast DNA decatenation that is mediated by human TOP2α and TOP2β in vitro with IC50 of 2.8 and 0.42 uM, respectively.

Boc-MLF (TFA) is a peptide, used as a specific formyl peptide receptor (FPR) antagonist, also inhibits the signaling through formyl peptide receptor like 1 (FPRL1) at higher concentrations.

Boldenone undecylenate(Equipoise) is a synthetic steroid which has a similar effect as the natural steroid testosterone; it is frequently used in veterinary medicine, though it is also used in humans.

Borussertib is a potent, first-in-class, covalent-allosteric AKT inhibitor.

BOS172722 (BOS-172722) is a potent, selective MPS1 kinase inhibitor with biochemical IC50 of 11 nM, 100-fold selectivity over CDK2.

Bosentan is a competitive and dual antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors.

Box5 is a Wnt5a-derived N-butyloxycarbonyl hexapeptide (t-Boc-Met-Asp-Gly-Cys-Glu-Leu), acts as an Wnt5a antagonist.

BP897 is a partially selective D3 dopamine receptor agonist.

BPIPP is an inhibitor of GC-C (guanylyl cyclase type C) that inhibits stimulation of guanylyl cyclase and adenylyl cyclase, suppresses cGMP accumulation in a variety of cell lines (IC50=3.4-11.2 uM).

BPK-29 is a covalent, specific small molecule that disrupts NR0B1 protein complexes and impairs the anchorage-independent growth of KEAP1-mutant cancer cells.

BPN-15606 (BPN15606) is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 by SHSY5Y neuroblastoma cells with IC50 of 7 nM.

BPO-27 racemate is a potent CFTR inhibitor with an IC50 of 8 nM.

BPR1J373 is a potent, orally available multitargeted kinase inhibitor, potently inhibits FLT3, c-KIT, VEGFR1-3, Aurora A, PDGFRα, PDGFRβ, RET, and SRC with IC50 values of <100 nM.

BPR1K653 is a novel potent Aurora kinase inhibitor that inhibits Aurora-A and Aurora-B with IC50 of 24 nM and 45 nM, respectively.

BQ-788 sodium salt is a potent, selective ETB receptor antagonist (IC50 = 1.2 nM for inhibition of ET-1 binding to human Girardi heart cells); poorly inhibited the binding to ET A receptors in human neuroblastoma cell line SK-N-MC cells (IC(50), 1300 nM).

BQU-082 is a novel potent small GTPase Ral (Ras-like) inhibitor with IC50 of 1.7 uM, displays a dose dependent effect on RalA and RalB activity in H2122 spheroids using the common RalBP1 pull-down assay..

BR101549 (BR-101549) is a novel PPARγ non-TZD agonist with EC50 of 1.73 uM (Amax 120%)..

BR103 is a potent, metabolically stable and highly selective small molecule agonist of complement C3a receptor (C3aR) with EC50 of 22 ± 8  nM.

BR111 is a potent, highly selective and orally active antagonist of complement C3a receptor (C3aR) with IC50 of 85 ± 40  nM (inhibition of hC3a induced Ca2+ release on human macrophages).

BR351 is a brain penetrant MMP inhibitor with IC50s of 4, 2, 11, 50 nM for MMP2, MMP8, MMP9 and MMP13, respectively. Potential tools for the molecular imaging of activated MMPs with PET.

BR351 precursor is a precursor of BR351. BR351 is a brain penetrant MMP inhibitor with IC50s of 4, 2, 11, 50 nM for MMP2, MMP8, MMP9 and MMP13, respectively. Potential tools for the molecular imaging of activated MMPs with PET.

BRACO-19 is a potent small molecule Telomerase inhibitor (IC50=115 nM) that inhibits expression of human telomerase reverse transcriptase (hTERT).

BRACO19 is a telomerase inhibitor that stabilizes G-quadruplexes, targeting telomeric G-quadruplexes, inducing DNA damage and cell-cycle arrest.

Bractoppin is a potent, small-molecule chemical inhibitor that specific selectively blocks phosphopeptide recognition by the BRCA1 tBRCT domain with binding IC50 of 74 nM; shows no inhibition for recognition of cognate biotinylated phosphopeptides to the TOPBP1 tBRCT 7/8, or GRB2 SH2 proteins; engages BRCA1 tBRCT residues recognizing pSer in the consensus motif, pSer-Pro-Thr-Phe, plus an abutting hydrophobic pocket; inhibits substrate recognition detected by Förster resonance energy transfer, and diminishes BRCA1 recruitment to DNA breaks, in turn suppressing damage-induced G2 arrest and assembly of the recombinase, RAD51; selectively interrupts BRCA1 tBRCT-dependent signals evoked by DNA damage.

Bradykinin is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also recognized as a neuromediator and regulator of several vascular and renal functions.

Bragsin1 (Bragsin 1) is a specific inhibitor of the ArfGEF BRAG2, affects the trans-Golgi network in a BRAG2- and Arf-dependent manner in cells (IC50=3 uM).

BRD 0476 (ML187) is a selective, moderate inhibitor of ubiquitin-specific peptidase 9X (USP9X), inhibits pancreatic β-cell apoptosis that inhibits IFN-γ-induced JAK2 and STAT1 signaling to promote β-cell survival.

BRD 4354 is a moderately potent inhibitor of HDAC5 and HDAC9, with IC50s of 0.85 and 1.88 μM, respectively.

BRD 7389 is an inhibitor of ribosomal S6 kinases (RSK) with IC50 of 1.5 uM, 2.4 uM, and 1.2 uM for RSK1, RSK2, and RSK3, respectively.

BRD 8184 is a potent, selective HDAC6 inhibitor with IC50 of 8 nM, weakly inhibits HDAC2 and HDAC8 (IC50=0.34 and 1.33 uM),has no activity for HDAC4 (IC50>30 uM)..

BRD 8430 is a potent, selective class I HDAC inhibitor (HDAC1>2 >3) with IC50 of 69 nM/560/1300 nM for HDAC1/2/3, respectively.

BRD 8899 is a potent and selective inhibitor of the serine/threonine kinase STK33 with IC50 of 0.11 nM (25 uM ATP).

BRD 9876 is an ATP- and ADP-competitive Eg5 (kinesin-5) inhibitor with Ki of 4 nM, selectively inhibits microtubule-bound Eg5 and inhibits multiple myeloma cell growth (IC50=2.2 uM).

BRD0209 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 19 nM/5 nM for GSK3α/GSK3β respectively.

BRD0705 is a potent, paralog-selective GSK3α inhibitor with IC50 of 66 nM, 8-fold selectivity over GSK3β (IC50=515 nM).

BRD10330 (BRD-10330) is a small molecule that upregulates IL-10 production in BMDCs.

BRD1172 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 3 nM/10 nM for GSK3α/GSK3β, respectively..

BRD1240 is a small-molecule probe that can suppress V-ATPase function, inhibits lysosomal acidification and blocks the maturation of autophagosomes to autolysosomes.

BRD1652 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 0.4 nM/4 nM for GSK3α/GSK3β respectively.

BRD1991 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity..

BRD2492 is a highly potent, selective HDAC1/2 inhibitor (IC50=2/19 nM, respectively) that displays excellent selectivity versus HDAC3 (IC50=2.08 uM, ≥110-fold selectivity) and all other HDAC isoforms, increases caspase-3 activation..

BRD2879 (BRD-2879) is a potent, selective inhibitor of IDH1-R132H mutant with IC50 of 50 nM, inhibits cell-based production of R-2HG with EC50 of 0.3 uM.

BRD3308 is a potent, selective HDAC3 inhibitor with IC50 of 54 nM, displays >20-fold selectivity over HDAC1 and HDAC2, >500-fold selectivity over other HDAC isoforms.

BRD3731 is a potent, selective GSK3β inhibitor with IC50 of 15 nM, 14-fold selectivity for GSK3β over GSK3α (IC50=215 nM).

BRD4 degrader AT1 is a highly selective Brd4 degrader based on PROTAC technology, with a Kd of 44 nM for Brd4BD2 in cells.

BRD4 inhibitor Compound V is a domain-selective inhibitor of BRD4 with IC50 of 1.8 uM for BRD4 BD1, displays 6- and 16-fold selectivity for BRD4 over BRD2 and BRD3, respectively.

BRD50837 is a potent, selective, small-molecule inhibitor of the Sonic Hedgehog (Shh) pathway with EC50 of 90 nM, partially lowers Gli1 expression at concentrations of 2 uM, a useful probe of Shh signaling pathway. .

BRD5459 is a nontoxic enhancer of reactive oxygen species (ROS) that strongly elevates markers of oxidative stress without causing cell death, ROS inducer..

BRD5529 is a small-molecule inhibitor that disrupts the interaction of CARD9-E3 ubiquitin ligase TRIM62 with IC50 of 8.6 uM.

BRD56491 is a nontoxic enhancer of reactive oxygen species (ROS) that strongly elevates markers of oxidative stress without causing cell death, ROS inducer..

BRD5814 is a potent, selective, highly brain penetrant β-arrestin biased dopamine D2 receptor (D2R) antagonist with Ki of 0.27 uM.

BRD6851 is a potent, cell-active Hedgehog (Hh) pathway inhibitor with IC50 of 0.4 uM against C3H10T1/2 cells undergoing Hh-induced activation acts predominantly as Smo antagonist.

BRD9092 is a nontoxic enhancer of reactive oxygen species (ROS) that strongly elevates markers of oxidative stress without causing cell death, ROS inducer..

BRD9526 is a potent, small-molecule inhibitor of the Sonic Hedgehog (Shh) pathway with EC50 of 60 nM, partially lowers Gli1 expression at concentrations of 10 uM, a useful probe of Shh signaling pathway. .

BRD9757 is a potent, selective HDAC6 inhibitor with IC50 of 8 nM, displays >20-fold selectivity over HDAC1/3 and other HDAC isoforms..

BRD9-IN-28 is a highly potent and selective BRD7/9 bromodomain inhibitor with pIC50 of 6.9, Kd of 68 nM for BRD9.

BRD-IN-17 is a cell permeable, family VIII bromodomain tool compound with additional PB1(2) activity over and above that of PFI-3.

BRD-IN-26 is a potent bromodomain inhibitor that binds the fifth bromodomain of PB1 with a KD of 124 nM, SMARCA2B and SMARCA4 with KD values of 262 and 417 nM, respectively.

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells.

Brequinar sodium (DuP-785, Brequinar, NSC 368390) is a potent and selective inhibitor of DHODH with IC50 of 20 nM, triggers differentiation in the ER-HoxA9, U937, and THP1 cells with an ED50 of 1 uM.

Brigatinib (AP-26113, AP26113) is a potent, selective, second generation ALK inhibitor with IC50 of 0.62 nM, exhibits about fivefold greater potency in vitro compared with crizotinib.

Brinzolamide is a potent carbonic anhydrase II inhibitor with IC50 of 3.19 nM.

Brivudine is a thymidine analogue with antiviral activity, indicated for the early treatment of acute herpes zoster.

BRK inhibitor P21d is a potent, selective, cell permeable inhibitor of breast tumor kinase (Brk, PTK6) with IC50 of 30 nM, shows no inhibitory activity against Aurora B and Lck (IC50>20 uM).

BRL 37344 is a potent and selective β3 adrenoceptor agonist with Ki of 287 nM.

BRL 52537 is a selective κ/μ opioid receptor agonist.

BRL 54443 is a 5-HT1E and 5-HT1F receptor agonist with pKi of 8.7 and 9.25, respectively, with a weak binding affinity for 5-HT1A, 5-HT1B, 5-HT1D receptors.

BRL-15572 2Hcl is a 5-HT1D receptor antagonist with pKi of 7.9, also shows a considerable affinity at 5-HT1A and 5-HT2B receptors, exhibiting 60-fold selectivity over 5-HT1B receptor.

BRL-50481 is a novel and selective inhibitor of phosphodiesterase (PDE) 7 with a Ki value, derived from secondary (Dixon) plots, of 180±10 nM, being at least 200-fold selective for hrPDE7A1 over all other PDEs.

Bromocriptine (2-Bromoergocriptine.

Bromocriptine (CB-154) is a dopamine D2 receptor agonist (Ki=3 nM) and and various serotonin receptors, also inhibits the release of glutamate by reversing the glutamate GLT1 transporter.

Bromotriazine (BTZ) is a covalent probe against bromodomain containing proteins with selectively targeting non-catalytic, highly conserved amino acid residues..

BRPF1B TRIM24-IN-34 is a selective BRPF1B/TRIM24 dual inhibitor that binds with KD of 137 and 222 nM, respectively.

Brusatol (NSC 172924, (+)-Brusatol) is a quassinoid extracted from Brucea Esters, can inhibit HIF-1 signaling pathway, also is a potent Nrf2 inhibitor.

Bryostatin 1 (NSC 339555) is a macrocyclic lactone derived from a marine invertebrate, fuctions as an activator of PKC with high binding affinity (Ki=1.35 nM).

BS148 (BS-148) is a potent, selective σ2 receptor agonist with pKi of 7.71, displays 25-fold selectivity over σ1.

BS-194 is a selective and potent CDK inhibitor, which inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 with IC50 values of 3, 30, 30, 250, and 90 nM respectively.

BSI-201 (Iniparib; NSC-746045) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC).

Btk inhibitor 2 is a Bruton's tyrosine kinase (BTK) inhibitor extracted from patent US 20170224688 A1.

BTK inhibitor 4b is a potent, highly selective inhibitors of BTK with IC50 of 4.2 and 0.9 nM against activated and unactivated BTK, respectively.

BTK PROTAC 10 is a novel potent PROTAC for BTK with DC50 of 1.1 nM in cultured Ramos cells.

BTK PROTAC 9 is a novel potent PROTAC for BTK with DC50 of 5.9 nM in cultured Ramos cells, requires simultaneous engagement of BTK and CRBN to effectively degrade BTK.

BTK-030 is a novel BTK inhibitor.

BTK-IN-23 is a highly potent and selective Btk inhibitor with IC50 of 3 nM.

BTRX-335140 (CYM-53093, BTRX335140, CYM53093) is a potent, selective, orally active κ opioid receptor (KOR) antagonist with IC50 of 0.8 nM.

BTT-266 (BTT266) is a voltage-gated CaV2.2 calcium channel inhibitor that disrupts the CaVα·CaVβ3 protein-protein interaction, directly binds to CaVβ3 with Kd of 3.6 uM.

BTT-369 (BTT369) is a voltage-gated CaV2.2 calcium channel inhibitor that disrupts the CaVα·CaVβ3 protein-protein interaction with Ki of 2.0 uM in FP assays.

BTX161 is a thalidomide analog that mediates degradation of CKIα better than lenalidomide in human AML cells and activates DDR and p53, while stabilizing the p53 antagonist MDM2.

BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA with IC50 of 5 uM.

BTZ043 racemate is a decaprenylphosphoryl-β-D-ribose 2-epimerase (DprE1) inhibitor acting as a new antimycobacterial agent that kill Mycobacterium tuberculosis.

BTZO-1 is a cardioprotective agent and Macrophage migration inhibitory factor (MIF) activator, binds to MIF with Kd of 68.6 nM, regulates ARE-mediated gene expression.

BTZO-15 is an active BTZO-1 derivative for ARE-activation with a favorable ADME-Tox profile, induces expression of heme oxygenase-1 (HO-1) and inhibits NO-induced cell death in IEC-18 cells.

BTZO-2 is an active BTZO-1 derivative, an antioxidant response element-activator, provides protection against lethal endotoxic shock in mice..

BU09059 is a potent, selective, short-acting kappa-opioid receptor antagonist with Ki of 1.72 nM, displays 15- and 616-fold selectivity over μ- and δ-receptors respectively.